



## **Ad Scientiam facilitates access for patients with multiple sclerosis to MSCopilot®, faced with Covid-19**

**Paris, June 9, 2020 - As lockdown measures begin to decrease in France, people with neurological or psychiatric diseases are still at risk from Covid-19. To support these patients, Ad Scientiam - a startup located within the iPEPS incubator - The Healthtech Hub of the Brain Institute - is accelerating the distribution of MSCopilot®, the first CE marked medical device allowing the monitoring of patients with multiple sclerosis.**

By including their work in a research approach to improve the care, monitoring and rehabilitation of patients, Ad Scientiam and the Brain Institute, where the start-up is incubated, confirmed their commitment to understanding neuropsychiatric diseases.

Patients with MS are particularly at risk in the current context of the Covid-19 pandemic, and the overloading of the healthcare system in recent months has resulted in an interruption of medical monitoring which will not resume for several weeks.

It is to alleviate the disruption of this care and the isolation of these patients that Ad Scientiam is now accelerating the distribution of MSCopilot®.

Previously performed during a consultation with the neurologist, registration and activation of the application is now done online and information documents are sent to the patient by email or post.

In addition, patient support in getting started with the app is carried out completely remotely using various digital media (videos, tutorials, newsletters) and the doctor-patient link is maintained thanks to the feedback of patient data to the neurologist and teleconsultations.

For their part, the referring physician can analyze their patients' data, monitor their state of health and efficiently prepare for consultations.

Selected by the Health Innovation Coalition - Health Crisis, MSCopilot® is a mobile application developed in collaboration with patients and doctors by Ad Scientiam at the Brain Institute and the Pitié-Salpêtrière hospital.

MSCopilot® and other medical devices designed by Ad Scientiam make it possible to measure parameters that are difficult to follow between consultations, such as motor skills, cognition, sleep or even mood. This data is then transmitted safely to the referring physician.

This evolution represents one more step towards improving patient care. Ad Scientiam thus continues to mobilize its environment (patients, associations and healthcare professionals) to make MSCopilot® a real life companion, creator of links between patients and doctors.

### ***About MSCopilot***

MSCopilot® is the first and only CE-marked software medical device for the self-assessment of MS patients in their daily lives. It captures over 350 digital biomarkers that provide objectivity to MS-related symptoms recorded through the patients' smartphones. The results generated are shared

with their healthcare providers and provide valuable information for their clinical decision-making. The patient remains in control of their data. MSCopilot®, which currently has over 3,500 users, is also used in several clinical studies.

For more information, follow the MSCopilot® [Facebook page](#) or visit the website [mscopilot.com](https://mscopilot.com)

### ***About Ad Scientiam***

At Ad Scientiam, we strongly believe that continuously measuring the evolution of severe and disabling diseases in real life is key to providing better care.

We make these evolutions visible, hitherto undetectable, through the design and clinical validation of digital biomarkers. These are derived from data collected via a digital tool such as the smartphone, and transformed by proprietary algorithms.

This scientific and technological challenge should now allow for each patient to be an actor in their own health and for healthcare professionals to offer more individualized and more efficient care. Ad Scientiam thus participates in the development of future treatments and in the reduction of the societal and economic impacts of diseases.

Thanks in particular to our ISO 13485 certification, our biomarkers are destined to become new international clinical standards.

Hospital institutions like the Brain Institute (ICM) and pharmaceutical companies like Biogen, Janssen, Roche, Pfizer, Vertex and Novartis have already trusted us.

In 2019, Ad Scientiam launched MSCopilot®, the first and only CE marked software medical device for self-assessment of patients with multiple sclerosis. New devices are being validated in neuroscience, rare diseases and mental disorders.

For more information, follow the Ad Scientiam [LinkedIn page](#) and [Facebook page](#) or visit the website [adscientiam.com](https://adscientiam.com)